Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil

N/ACompletedNCT03719287

Solventum US LLC295 enrolled

Overview

A multi-center, national prevalence study where: (1) baseline SPIVC therapy complications of hospitalized adult patients that meet the inclusion/exclusion criteria of the study and (2) the compliance of clinicians to the Hospital's evidence based practice will be measured in Brazil.

At each participating research site, select nurse clinicians who are experienced or experts in short peripheral I.V. catheter (SPIVC) therapy, will audit medical records and observe the SPIVC sites of adult patients in various hospital wards until a minimum total of 300 SPIVC sites are audited among 3 Brazilian acute care hospitals. The wards audited will be selected by the Investigator and will be audited during a specified time period until at least 100 SPIVCs are audited. The time to complete the study will depend on the size of the select wards, the number of nurse auditors and the number of monitoring visits required. There are no treatments. The short peripheral I.V. catheter-related medical devices (products) observed during the study are currently approved by Brazil regulatory agencies, purchased by the hospital and available to the clinician at the time of the study.

Study Type

OBSERVATIONAL

Enrollment

295

Conditions

Infusion Site Injury

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subject, aged 18 years or older at the time of the study's audit of the ward; * Subject admitted into one of the wards audited at the study site; * Subject available for observation at the time of the audit; * Subject with at least one inserted PIVC; * Subject that voluntarily signed and dated the informed consent form (ICF) prior to study entry, if required by the study site's Ethics Committee. Exclusion Criteria: * Subject under treatment at the study site's outpatient clinics; * Subject admitted into a mental health ward, emergency ward or burn unit; * Subject awaiting transfer to another facility.

Locations (3)

Hospital Erasto Gaertner (HEG)

Curitiba, Paraná, Brazil

Centro de Pequisa Clinica Sao Lucas

Campinas, São Paulo, Brazil

Universidade Federal de Sao Paulo

São Paulo, Brazil

Outcomes

Primary Outcomes

Percentage of PIVCs Sites With at Least One Clinical or Mechanical Complication (PIVC-related Complications)

Clinical complications are: phlebitis (grade 1-4), Hematoma, Ecchymosis, Skin injury, Local infection. Mechanical complications are: Catheter dislodgement, Occlusion, Extravasation, Infiltration (grade 1-4), Leaking at the insertion site. Prevalence (%) = (Number of audited PIVC sites with at least one clinical or mechanical complication ÷ Number of audited PIVC sites) x 100

Time frame: From PIVC insertion to the audit, up to 7 days.

Secondary Outcomes

Percentage of PIVC Sites With at Least One Clinical and One Mechanical Complication (PIVC-related Clinical and Mechanical Complications).

Clinical complications are: phlebitis (grade 1-4), Hematoma, Ecchymosis, Skin injury, Local infection. Mechanical complications are: Catheter dislodgement, Occlusion, Extravasation, Infiltration (grade 1-4), Leaking at the insertion site. Prevalence (%) = (Number of audited PIVC sites with at least one clinical and one mechanical complication ÷ Number of audited PIVC sites) x 100 PIVC sites with at least one clinical complication and one mechanical complication as well.

Time frame: From PIVC insertion to the audit, up to 7 days.

Percentage of PIVC Sites With at Least One Clinical Complication

Specific clinical complications are: phlebitis (grade 1 - 4), Hematoma, Ecchymosis, Skin injury, Local infection. Prevalence (%) = (Number of audited PIVC sites with at least one clinical complication ÷ Number of audited PIVC sites) x 100

Time frame: From PIVC insertion to the audit, up to 7 days.

Percentage of PIVC Sites With at Least One Mechanical Complication

Mechanical complications are: Catheter dislodgement, Occlusion, Extravasation, Infiltration (grade 1-4), Leaking at the insertion site. Prevalence (%) = (Number of audited PIVC sites with at least one mechanical complication ÷ Number of audited PIVC sites) x 100

Time frame: From PIVC insertion to the audit, up to 7 days.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.